Secondary progressive


Also found in: Acronyms.

Secondary progressive

A pattern of symptoms of multiple sclerosis in which there are relapses and remissions, followed by more steady progression of symptoms.
Mentioned in: Multiple Sclerosis
References in periodicals archive ?
MS, which affects approximately 2.3 million people worldwide[7], is often characterized into three forms: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS - often defined as cognitive and physical changes, and an overall accumulation of disability[8]) and primary progressive MS (PPMS)[9].
It affects around 2.3 million people globally and comes in three forms: relapsing-remitting, secondary progressive, and primary progressive.
For example, early spinal cord damage indicated people were much more likely to go on to develop the secondary progressive form of MS, which currently has no treatment and is where disability gets steadily worse.
Key elements of MediciNova's Phase 3 clinical trial plan for MN-166 in progressive MS include the following: MediciNova's Phase 3 trial will enroll only subjects with secondary progressive MS without relapses.
Progressive MS is divided into primary progressive MS (approximately 15% of all patients) and secondary progressive MS that follows a period of relapsing-remitting disease course [1].
In the UK people are most likely to find out they have MS in their thirties, forties and fifties There are three main types of MS - relapsing remitting, primary progressive and secondary progressive. Walks can be any distance and take place anywhere.
The US FDA has approved the company's MAVENCLAD (cladribine) for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS).
Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Robert Zivadinov, M.D., Ph.D., from the University at Buffalo in New York, and colleagues conducted a prospective study between March 2009 and November 2013 involving 600 participants with MS (452 with relapsing-remitting MS and 148 with secondary progressive MS) and 250 age- and sex-matched healthy controls.
After many years (usually decades), many, but not all people, with relapsing remitting MS go on to develop secondary progressive MS.
Novartis achieved positive results from its Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS).
Pharmascroll has generated over 30 market research reports in multiple disease indications including Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis and Migraine disease indications in less than a year of the launch of company.

Full browser ?